{"id":744902,"date":"2014-11-06T09:08:00","date_gmt":"2014-11-06T09:08:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/"},"modified":"2023-03-22T00:04:49","modified_gmt":"2023-03-22T04:04:49","slug":"new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/","title":{"rendered":"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time"},"content":{"rendered":"<p class=\"bwalignc\">       By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been        Presented     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that in November and December, data will be presented<br \/>\n      for the first time investigating the use of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in advanced melanoma<br \/>\n      in comparison to chemotherapy, and in relapsed\/refractory classical<br \/>\n      Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer<br \/>\n      (TNBC). These studies will be presented in oral sessions at the Society<br \/>\n      for Melanoma Research (SMR) 2014 International Congress, Nov. 13 \u2013 16,<br \/>\n      the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 \u2013<br \/>\n      9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 \u2013 13,<br \/>\n      respectively. By the end of 2014, data on anti-tumor activity of<br \/>\n      KEYTRUDA as monotherapy will have been presented in seven different<br \/>\n      tumor types.\n    <\/p>\n<p>\n      \u201cOur focus on evaluating KEYTRUDA as a monotherapy is enabling Merck to<br \/>\n      rapidly advance the clinical development of our anti-PD-1 therapy,\u201d said<br \/>\n      Dr. Roy Baynes, senior vice president, Global Clinical Development,<br \/>\n      Merck Research Laboratories. \u201cWe look forward to the first comparative<br \/>\n      data in advanced melanoma, and new data in advanced triple negative<br \/>\n      breast cancer and classical Hodgkin Lymphoma being presented. We<br \/>\n      continue to expand our immuno-oncology clinical program with KEYTRUDA<br \/>\n      both as monotherapy and in combination with other agents.\u201d\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg every<br \/>\n      three weeks for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. This indication is<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. An improvement in survival or disease-related<br \/>\n      symptoms has not yet been established. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Merck data to be presented at SMR 2014 include:<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i><b>Late Breaker Oral Presentation:<\/b><\/i> <b>A Randomized<br \/>\n        Controlled Comparison of Pembrolizumab (MK-3475) and Chemotherapy in<br \/>\n        Patients with Ipilimumab-Refractory Melanoma (KEYNOTE-002).<\/b> A.<br \/>\n        Ribas. Sunday, November 16, 8:50 AM-10:25 AM CET. Location:<br \/>\n        Kongresshaus, First Floor.\n      <\/li>\n<\/ul>\n<p>\n      <b>Merck data to be presented at the ASH Annual Meeting include:<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #290) Oral Presentation: <\/b><\/i><b>PD-1 Blockade with<br \/>\n        the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with<br \/>\n        Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure:<br \/>\n        Preliminary Results From a Phase 1b Study (KEYNOTE-013). <\/b>C.<br \/>\n        Moskowitz. Monday, December 8, 7:15 AM-7:30 AM PST. Location: Moscone<br \/>\n        Center, West Building, 3009-3011-3022-3024.\n      <\/li>\n<\/ul>\n<p>\n      <b>Merck data to be presented at SABCS include:<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #S1-09) Oral Presentation: <\/b><\/i><b>A Phase 1b Study<br \/>\n        (KEYNOTE-012) of Pembrolizumab (MK-3475) in Patients with Advanced<br \/>\n        Triple-Negative Breast Cancer. <\/b>R. Nanda. Wednesday, December 10,<br \/>\n        10:45 AM-11:00 AM CST. Location: Henry B. Gonzalez Convention Center,<br \/>\n        Hall D.\n      <\/li>\n<\/ul>\n<p>\n      For more information including a complete list of abstract titles,<br \/>\n      please visit the SMR 2014 website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.melanomacongress.com&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=www.melanomacongress.com&amp;index=1&amp;md5=b22ca6ab1b60c8535ff63ea37e29d361\" rel=\"nofollow\">www.melanomacongress.com<\/a>,<br \/>\n      the ASH Annual Meeting website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hematology.org%2FAnnual-Meeting&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=www.hematology.org%2FAnnual-Meeting&amp;index=2&amp;md5=90ce727167de973485c7f15e8fe85338\" rel=\"nofollow\">www.hematology.org\/Annual-Meeting<\/a>,<br \/>\n      and the SABCS website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sabcs.org&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=www.sabcs.org&amp;index=3&amp;md5=d737dd26d01997619a516ba9789356fe\" rel=\"nofollow\">www.sabcs.org<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=4&amp;md5=e22371ef842ae78f339f1fe79f3b3a52\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=e169d6d4a5badecd1d3f67c9856e2255\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIedEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrhdLCXCXCOsVHkiP9C9jDYunNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzztxwgD7GV&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=cffe90289733be1fb85e82507dfce50c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIgdEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrjdLCXCXCM0jKSYxmFnBYl-dyF3P7DDCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96Qrzzu-jj&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=89c9a370d5514e7a193b1d36d362cdbf\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2FavndzgA76Qm4m71PwV5ATsSCyOeu7nju76QQmhPMWXba9Jd5AsYeKCYYrhKyqeknbKc8CRvzoHm5GDR8BF_GEacmm8DR8qvOVINpoyvkxF_bCTnbI9LIfZvxOr_nKnjpvuV5AseVqWdAklrFFYG7DR8OJMddICTPtPtPo08JlKrp3-nNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzzqvgF&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=cce449373ef6831c045f2cf49839558c\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=92ae43186cc3b7ee726c26e192ef27c7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      # # #\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=10&amp;md5=82efb599a660692992a2811610e8adb8\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=50978189&amp;newsitemid=20141106005811&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=11&amp;md5=5cb828c93daf60d754c5b15340ed6d3f\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of Merck<br \/>\n      &amp; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141106005811r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Claire        Mulhearn, 908-236-1118<br \/>or<br \/>Investor:<br \/>Joseph Romanelli,        908-423-5185<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA \u00ae (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in advanced melanoma in comparison to chemotherapy, and in relapsed\/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 \u2013 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 \u2013 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 \u2013 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types. \u201cOur focus on evaluating KEYTRUDA as a monotherapy is enabling Merck to rapidly advance the clinical development of our anti-PD-1 therapy,\u201d said Dr. Roy Baynes,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-744902","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA \u00ae (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in advanced melanoma in comparison to chemotherapy, and in relapsed\/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 \u2013 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 \u2013 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 \u2013 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types. \u201cOur focus on evaluating KEYTRUDA as a monotherapy is enabling Merck to rapidly advance the clinical development of our anti-PD-1 therapy,\u201d said Dr. Roy Baynes,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\\\/\",\"name\":\"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-11-06T09:08:00+00:00\",\"dateModified\":\"2023-03-22T04:04:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/","og_locale":"en_US","og_type":"article","og_title":"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA \u00ae (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in advanced melanoma in comparison to chemotherapy, and in relapsed\/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 \u2013 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 \u2013 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 \u2013 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types. \u201cOur focus on evaluating KEYTRUDA as a monotherapy is enabling Merck to rapidly advance the clinical development of our anti-PD-1 therapy,\u201d said Dr. Roy Baynes,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:49+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/","name":"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-11-06T09:08:00+00:00","dateModified":"2023-03-22T04:04:49+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-studies-investigating-the-use-of-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-melanoma-compared-to-chemotherapy-in-classical-hodgkin-lymphoma-and-in-triple-negat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Studies Investigating the Use of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"74c9b92f-d9ba-4c91-b061-2756394814f4","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Studies-Investigating-the-Use-of-KEYTRUDA-pembrolizumab-Mercks-Anti-PD-1-Therapy-in-Advanced-Melanoma-Compared-to-Chemotherapy-in-4S590.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744902\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744902"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}